Today's Value-Added Medicines and 505(b)(2) professionals stitch together fragmented advice from five or more siloed events a year — a regulatory webinar here, an IP workshop there, a BD panel somewhere else.
HYBRIDGE is the first industry-led, end-to-end conference that puts ideation, IP, non-clinical, clinical, regulatory (US + EU), market access, BD and licensing in the same room.
Curated by Annion, HYBRIDGE is built on three principles: industry voice over vendor pitch, end-to-end scope over siloed sessions, and a working network of peers who have already done it.